ENTA · Enanta Pharmaceuticals Inc
Market Cap
$377.47M
Shares
29.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.96
Open$12.83
Day$12.59–13.04
52W close$7.17–16.85
Avg vol 30d225K
Short int2.6M · 9.0% float · 10.2d
Short vol51%
Last earningsNov 25, 2024
DataJan 2020–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$65.26M
Trailing 12 months
Net income (TTM)
−$63.23M
Trailing 12 months
Revenue growth YoY
-21.6%
Year over year
Operating margin
-90.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.1%
Year over year · more shares
Price change (1Y)
+49.7%
Trailing year
Short interest
9.0%
Latest settlement · 10.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−4%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
60%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+4%
trailing
YTD return
−18%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.98% of float · ▼ -2.4% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-32.2M
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Nov 22, 2021
Research and development expense
· fiscal 2022
$150M – $170M
General and administrative expense
· fiscal 2022
$35M – $41M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
−4%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
60%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.98% of float · ▼ -2.4% MoM · 10.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $13 · 60%
Range high $17
vs 200-day avg -5%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTA
this stock
Enanta Pharmaceuticals Inc
|
$377.47M | -17.8% | +16.5% | — | 9.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTA | -7.6% | -3.6% | +3.6% | -2.8% | -17.8% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.4% | -1.8% | -14.2% | -2.4% | -29.9% |
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
40 filings
40 filers
Visit website
Investor relations